Cardiomyopathy, familial dilated

被引:0
|
作者
Matthew RG Taylor
Elisa Carniel
Luisa Mestroni
机构
[1] University of Colorado Health Sciences Center,University of Colorado Cardiovascular Institute and Adult Medical Genetics Program, Department of Internal Medicine
来源
Orphanet Journal of Rare Diseases | / 1卷
关键词
Genetic Counseling; Cardiac Resynchronization Therapy; Carvedilol; Angiotensin Converting Enzyme Inhibitor; Left Ventricular Assist Device;
D O I
暂无
中图分类号
学科分类号
摘要
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilatation and impaired systolic function. Patients with DCM suffer from heart failure, arrhythmia, and are at risk of premature death. DCM has a prevalence of one case out of 2500 individuals with an incidence of 7/100,000/year (but may be under diagnosed). In many cases the disease is inherited and is termed familial DCM (FDC). FDC may account for 20–48% of DCM. FDC is principally caused by genetic mutations in FDC genes that encode for cytoskeletal and sarcomeric proteins in the cardiac myocyte. Family history analysis is an important tool for identifying families affected by FDC. Standard criteria for evaluating FDC families have been published and the use of such criteria is increasing. Clinical genetic testing has been developed for some FDC genes and will be increasingly utilized for evaluating FDC families. Through the use of family screening by pedigree analysis and/or genetic testing, it is possible to identify patients at earlier, or even presymptomatic stages of their disease. This presents an opportunity to invoke lifestyle changes and to provide pharmacological therapy earlier in the course of disease. Genetic counseling is used to identify additional asymptomatic family members who are at risk of developing symptoms, allowing for regular screening of these individuals. The management of FDC focuses on limiting the progression of heart failure and controlling arrhythmia, and is based on currently accepted treatment guidelines for DCM. It includes general measures (salt and fluid restriction, treatment of hypertension, limitation of alcohol intake, control of body weight, moderate exercise) and pharmacotherapy. Cardiac resynchronization, implantable cardioverter defibrillators and left ventricular assist devices have progressively expanding usage. Patients with severe heart failure, severe reduction of the functional capacity and depressed left ventricular ejection fraction have a low survival rate and may require heart transplant.
引用
收藏
相关论文
共 50 条
  • [31] Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy
    Watanabe, K
    Saito, Y
    Ma, ML
    Wahed, M
    Abe, Y
    Hirabayashi, K
    Narasimman, G
    Wen, JA
    Suresh, P
    Ali, F
    Shirai, K
    Soga, M
    Nagai, Y
    Nakazawa, M
    Hasegawa, G
    Naito, T
    Tachikawa, H
    Kodama, M
    Aizawa, T
    Yamaguchi, K
    Takahashi, T
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 : S105 - S109
  • [32] Non-ischemic dilated cardiomyopathy and cardiac fibrosis
    Cojan-Minzat, Bianca Olivia
    Zlibut, Alexandru
    Agoston-Coldea, Lucia
    HEART FAILURE REVIEWS, 2021, 26 (05) : 1081 - 1101
  • [33] Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy
    Kanoupakis, Emmanuel M.
    Manios, Emmanuel G.
    Mavrakis, Hercules E.
    Kallergis, Eleftherios M.
    Lyrarakis, George M.
    Koutalas, Emmanuel P.
    Vardas, Panos E.
    CARDIOVASCULAR DRUGS AND THERAPY, 2008, 22 (03) : 169 - 176
  • [34] Late Gadolinium Enhancement in Patients with Nonischemic Dilated Cardiomyopathy
    Memon, Sarfaraz
    Ganga, Harsha V.
    Kluger, Jeffrey
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2016, 39 (07): : 731 - 747
  • [35] Differentiation between left bundle branch block (LBBB) preceded dilated cardiomyopathy and dilated cardiomyopathy preceded LBBB by cardiac magnetic resonance imaging
    Wang, Hui
    He, Yi
    Du, Xin
    Yao, Rui
    Chang, Sanshuai
    Guo, Fei
    Bai, Zhongle
    Lv, Qiang
    Liu, Xiaohui
    Dong, Jianzeng
    Ma, Changsheng
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2020, 43 (08): : 847 - 855
  • [36] Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient-Derived iPSC Model
    Wyles, S. P.
    Hrstka, S. C.
    Reyes, S.
    Terzic, A.
    Olson, T. M.
    Nelson, T. J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (03): : 158 - 167
  • [37] Current diagnostic strategies for dilated cardiomyopathy: a comparison of imaging techniques
    Porcari, Aldostefano
    De Angelis, Giulia
    Romani, Simona
    Paldino, Alessia
    Artico, Jessica
    Cannata, Antonio
    Gentile, Piero
    Pinamonti, Bruno
    Merlo, Marco
    Sinagra, Gianfranco
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (01) : 53 - 63
  • [38] Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure
    Bonnet, Damien
    Berger, Felix
    Jokinen, Eero
    Kantor, Paul F.
    Daubeney, Piers E. F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (10) : 1262 - 1272
  • [39] Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals
    Hershberger, Ray E.
    Morales, Ana
    Siegfried, Jill D.
    GENETICS IN MEDICINE, 2010, 12 (11) : 655 - 667
  • [40] Beta-blocker Therapy as a Treatment for Canine Dilated Cardiomyopathy
    Curby, B. J.
    AUSTRALIAN VETERINARY PRACTITIONER, 2009, 39 (02): : 70 - 75